본문 바로가기

5-Aminosalicylic Acid Azo-Coupled with a GPR109A Agonist Is a Colon-Targeted Anticolitic Codrug with a Reduced Risk of Skin Toxicity

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
MOLECULAR PHARMACEUTICS17(1) · pp.167 · 2020
피인용
Web of Science 14Scopus 15
FWCI (Scopus)
0
JCR IF
JCR 2019 4.321
ISSN
1543-8384

저자

  1. 정성근제1저자College of Pharmacy, Pusan National University, Busan, Republic of Korea
  2. 이한주College of Pharmacy, Pusan National University, Busan, Republic of Korea
  3. 김수진College of Pharmacy, Pusan National University, Busan, Republic of Korea
  4. 주상현College of Pharmacy, Pusan National University, Busan, Republic of Korea
  5. 김우성College of Pharmacy, Pusan National University, Busan, Republic of Korea
  6. Cho, HeeyeongBiotechnology & Therapeutic Division, Korea Research Institute of Chemical Technology, Daejeon 305-343, Republic of Korea
  7. Kim, Hyun YoungBiotechnology & Therapeutic Division, Korea Research Institute of Chemical Technology, Daejeon 305-343, Republic of Korea
  8. 허광범College of Pharmacy, Pusan National University, Busan, Republic of Korea
  9. 임은옥College of Pharmacy, Pusan National University, Busan, Republic of Korea
  10. 유진욱College of Pharmacy, Pusan National University, Busan, Republic of Korea
  11. 윤인수College of Pharmacy, Pusan National University, Busan, Republic of Korea
  12. 정연진교신저자College of Pharmacy, Pusan National University, Busan, Republic of Korea

초록

To develop a 5-aminosalicylic acid (5-ASA)-based anticolitic drug with enhanced therapeutic activity, a colon-targeted codrug constituting 5-ASA and a GPR109A agonist was designed. 5-ASA azo-coupled with nicotinic acid (ASA-azo-NA) was synthesized, and the colon specificity and anticolitic effects were evaluated. Approximately 89% of ASA-azo-NA was converted to 5-aminonicotinic acid (5-ANA) and 5-ASA after 24 h of incubation in the cecal contents. 5-ANA was identified as a GPR109A agonist (concentration that gives half-maximal response (EC50): 18 mu M) in a cell-based assay. Upon oral gavage of ASA-azo-NA (oral ASA-azo-NA) and sulfasalazine (oral SSZ), a colon-targeted 5-ASA prodrug, cecal accumulation of 5-ASA was comparable, and 5-ANA was barely detectable in the blood, while it was detected up to 62.7 mu M with oral 5-ANA. In parallel, oral ASA-azo-NA did not elicit an adverse skin response. In murine macrophage and human colon carcinoma cells, activation of GPR109A by 5-ANA elevated the level of the anti-inflammatory cytokine IL-10, suppressed NF-kappa B activation, and potentiated the inhibitory activity of 5-ASA on NF-kappa B. Oral ASA-azo-NA ameliorated rat colitis and was more effective than oral SSZ, which were substantially blunted following cotreatment with the GPR109A antagonist, mepenzolate. In conclusion, ASA-azo-NA is a colon-targeted anticolitic codrug with a reduced risk of skin toxicity induced by the GPR109A agonist, therapeutically surpassing a current 5-ASA-based anti-inflammatory bowel disease drug in a rat colitis model.

키워드

5-aminosalicylic acid5-aminonicotinic acidGPRI09Acolon-targeted drug deliverycodruginflammatory bowel diseaseNF-KAPPA-BNICOTINIC-ACIDDRUG-THERAPYBUTYRATERECEPTORNIACINPROCAINAMIDEPATHOGENESISINFLAMMATIONINHIBITIONGPR109A

식별자

Scopus EID
2-s2.0-85076239254
WoS UID
000506713600016